Stocks · News reference
Jazz Pharmaceuticals To Acquire Developer Of Epilepsy Therapy Biotech Actio Biosciences For $820M Up Front And Up To $500M In Contingencies
Actio Biosciences' lead clinical asset is ABS-1230, a novel, first-in-class small molecule precision therapy KCNT1 ion channel inhibitor. KCNT1+ epilepsy is a rare genetic developmental and epileptic encephalopathy
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 10, 2026, 11:37 AM
- Checked
- Aug 10, 2026, 11:37 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Deutsche Bank Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $300
Deutsche Bank analyst David Hoang maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy and raises the price target from $287 to $300.
Read original at benzingaMorgan Stanley Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $322
Morgan Stanley analyst Jeffrey Hung maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and raises the price target from $283 to $322.
Read original at benzingaThese Analysts Increase Their Forecasts On Jazz Pharmaceuticals
FDA approves JAZZ's Ziihera-containing combination regimens for HER2-positive gastroesophageal adenocarcinoma. JAZZ stock drops 0.8% to $258.14. Analysts raise price targets to $310 and $281 in response to positive earnings. Considering buying JAZZ? Here's what analysts say.
Read original at benzinga